Immunization Resources & Tools

     
  Careers & Information for Physicians  
       
     
  Immunization Resources & Tools  
       
     
  Northern Clinical Simulation  
       
     
  Palliative Care / End of Life Care  
       
     
  Pharmacy Practice Residency Program  
       
     
  Professional Practice  
       
 
 
     

This webpage is a communications tool to share and promote immunization information and resources with all Community Vaccine Providers (CVPs) within the Northern Health region.

The Community Vaccine Providers (CVP) Newsletter is one of Northern Health's communication tools. If you are interested in contributing to future issues of the newsletter or web page please contact Jill Walker, Interim Regional Manager Communicable Disease Program, Public Health at jill.walker@northernhealth.ca.

Community Vaccine Newsletter

WHAT'S NEW

Tetanus promotion, immunization and other vaccine awareness materials:

Spring has sprung into summer! With the warmer weather comes an increased risk of tetanus infection. This is a great time to promote tetanus vaccination in your community. 

It is ideal to have opportunistic conversations with your clients about their immunization history. However, having print materials on hand can also help raise awareness and spark conversation in your clinic. Immunize Canada has posters and brochures ready to print and display. Health Canada also has available FREE vaccine promoting resources for order as well as a vaccine promoting YouTube video - Vaccination: Are we there yet?

For more information on talking to clients about vaccinations, visit ImmunizeBC to access communication resources for health professionals.

Community Vaccine Providers-Improving Access to Immunization Services

Vaccination is considered one of the 12 great achievements in the history of public health. As public health associations in Canada point out, one hundred years ago infectious diseases were the leading causes of death worldwide. Now thanks to advances in vaccines and immunization they are the cause of less than 5% of all deaths in Canada. But the capacity to maintain our immunization efforts is always stretched. We can lose ground. That is why building an even stronger team across the whole health sector to contribute to our fight against infectious diseases has never been more important. Expanding the contribution of pharmacists in the vaccination efforts is another milestone in building a strong system for public health.

Ted Bruce
Co-Chair, Policy Advocacy Research Committee
Public Health Association of BC

Non-Publicly Funded Vaccines

Over the past decade, a number of important new vaccines have been approved for use in Canada but are not publicly-funded at this time. Healthcare providers such as physicians, public health nurses, pharmacists, and other vaccine providers should communicate relevant information about all available vaccines, publicly-funded or not, to allow patients to make informed decisions about their health. The following resources provide further information on non-publicly funded vaccines in Canada:

Select Recently Available
Vaccines in Canada

NACI Recommendations

  • Human Papilloma Virus (HPV) vaccine 
    • Gardasil®(HPV4 – types 6,11,16,18)
    • CervarixTM (HPV 2 – types 16,18)

Gardasil® (HPV4 vaccine) has been authorized for use in Canada since 2006 for the prevention of infection caused by HPV types 6, 11, 16 and 18 -related cancers and genital warts. Cervarix® (HPV2 vaccine) has been authorized for use in Canada since 2010 for the prevention of cervical cancer caused by HPV types 16 and 18.

  • Gardasil® or Cervarix® are recommended for: Females 9 through 26 years of age.
    Publicly Funded in BC? - Yes
  • Gardasil® is recommended for: Males between 9 and 26 years of age, including males who have sex with males.
    Publicly Funded in BC? - Yes
    • Men who have sex with men; street involved; HIV positive.
    • 9-18 years of age in care of Ministry of Children & Family.
    • 12-17 years of age in youth custody.

  • Cervarix® is not recommended for males at this time.

  • Gardasil® or Cervarix® may be administered to: Females over 26 years of age.
    Publicly Funded in BC? - No
  • Gardasil® may be administered to: Males over 26 years of age.
    Publicly Funded in BC? - No

HPV vaccines are not recommended for: Females or Males < 9 years of age as no immunogenicity or efficacy data are available in these groups.

  • Multicomponent Meningococcal serogroup B (4CMenB) vaccine
    • Bexsero®

The multicomponent meningococcal serogroup B (4CMenB) vaccine is the first available vaccine against serogroup B IMD in Canada. MenB is now the most prevalent serogroup in Canada, accounting for >50% of cases between 2002 and 2011 [5]. The vaccine is protective against strains that express antigens contained in the vaccine at sufficient levels. The 4CMenB vaccine is an immunogenic vaccine, though its effectiveness, impact on carriage and the duration of protection remains unknown.

  • Bexsero® is recommended for those greater than or equal to two months of age who:
    • Are at high risk of meningococcal disease caused by serogroup B N. meningitidis.
    • Have been in close contact with a case of Invasive Meningococcal Disease (IMD) caused by serogroup B N. meningitides.
    • Those who may be at risk during an outbreak caused by serogroup B N. meningitides.
    • Those who are without contraindication to the vaccine and wish to be immunized.

    • Publicly Funded in BC? - No
  • Quadrivalent Conjugate Meningococcal Vaccines (serogroups A, C, Y, W and W-135)
    • Nimenrix™
    • Menactra®
    • Menveo™

Invasive meningococcal disease (IMD) is a potentially fatal disease usually presenting as an acute febrile illness with rapid onset and features of meningitis or septicemia (meningococcemia), or both, and a characteristic non-blanching rash.

Nimenrix™ is a newly licensed quadrivalent (serogroups A, C, Y and W-135) meningococcal vaccine conjugated to the tetanus toxoid (TT).

  • For routine vaccination in adolescents, either monovalent meningococcal C conjugate or quadrivalent conjugate meningococcal vaccines can be used depending on local epidemiology and other programmatic considerations.
  • Publicly Funded in BC - Monovalent MenC - Yes
    Publicly Funded in BC? - Quadrivalent Meningococcal Vaccines - Yes. Fall 2016 included in the Grade 9 vaccination program
  • NimenrixTM, Menactra®, or MenveoTM is recommended for high risk individuals 2 years of age and older or for travellers 2 years and older going to areas where the meningococcal vaccine is recommended. Menveo™ is the only recommended product for individuals 2 months of age to less than 2 years of age with the same risk factors.
  • Publicly Funded in BC? - Yes (for medically high-risk individuals and close contacts to an IMD case)
    Publicly Funded in BC? - No (for travellers, research/laboratory personnel)
  • Herpes Zoster (shingles) vaccine (HZV)
    • Zostavax®

    HZV is a live, attenuated virus vaccine containing a lyophilized preparation of the Oka/Merck strain of varicella-zoster virus. Immunosuppressed persons are at increased risk for herpes zoster. ZOSTAVAX™ is indicated for the prevention of herpes zoster in patients with prior chickenpox infection.

  • Zoster is recommended for:
    • Persons 60 years and older without contraindications.
    • Individuals ≥50 years can be considered for immunization.

    • Publicly Funded in BC? - No